Do analysts rate KVAC or APLT?

Applied Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' higher possible upside, analysts clearly believe Applied Therapeutics is more favorable than Keen Vision Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has preferable earnings & valuation, KVAC or APLT?

Keen Vision Acquisition has higher earnings, but lower revenue than Applied Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Keen Vision Acquisition N/A N/A N/A N/A N/A Applied Therapeutics $1M 15.86 -$105.62M -$0.10 N/A

Is KVAC or APLT more profitable?

Keen Vision Acquisition's return on equity of 0.00% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Keen Vision Acquisition N/A N/A N/A Applied Therapeutics N/A -340.84% -175.00%

Do analysts rate APLT or BOLD?

Applied Therapeutics currently has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Applied Therapeutics is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is APLT or BOLD more profitable?

Boundless Bio's return on equity of -70.89% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% Boundless Bio N/A -70.89% -47.37%

Do analysts rate EXOZ or APLT?

Applied Therapeutics has a consensus price target of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is EXOZ or APLT more profitable?

eXoZymes' return on equity of -292.15% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -292.15% -158.66% Applied Therapeutics N/A -340.84% -175.00%

Applied Therapeutics (APLT) Competitors

$0.10 0.00 (0.00%)

As of 10/9/2026

Compare

APLT vs. KVAC, YARW, XLO, BOLD, and EXOZ

Should you buy Applied Therapeutics stock or one of its competitors? Applied Therapeutics's main competitors and comparable companies include Keen Vision Acquisition (KVAC), Yarrow Bioscience (YARW), Xilio Therapeutics (XLO), Boundless Bio (BOLD), and eXoZymes (EXOZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Applied Therapeutics compare to Keen Vision Acquisition?

Keen Vision Acquisition (NASDAQ:KVAC) and Applied Therapeutics (NASDAQ:APLT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

Applied Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' higher possible upside, analysts clearly believe Applied Therapeutics is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Keen Vision Acquisition has higher earnings, but lower revenue than Applied Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

Keen Vision Acquisition has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market.

Keen Vision Acquisition's return on equity of 0.00% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keen Vision Acquisition	N/A	N/A	N/A
Applied Therapeutics	N/A	-340.84%	-175.00%

In the previous week, Keen Vision Acquisition's average media sentiment score of 0.00 equaled Applied Therapeutics'average media sentiment score.

Company	Overall Sentiment
Keen Vision Acquisition	Neutral
Applied Therapeutics	Neutral

51.7% of Keen Vision Acquisition shares are held by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are held by institutional investors. 80.2% of Keen Vision Acquisition shares are held by insiders. Comparatively, 1.6% of Applied Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Keen Vision Acquisition and Applied Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Applied Therapeutics compare to Yarrow Bioscience?

Applied Therapeutics (NASDAQ:APLT) and Yarrow Bioscience (NASDAQ:YARW) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by company insiders. Comparatively, 3.0% of Yarrow Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Applied Therapeutics currently has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Yarrow Bioscience has a consensus price target of $58.00, suggesting a potential upside of 194.27%. Given Applied Therapeutics' higher probable upside, equities analysts plainly believe Applied Therapeutics is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Yarrow Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Applied Therapeutics has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Yarrow Bioscience's return on equity of -84.40% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%

In the previous week, Yarrow Bioscience had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for Yarrow Bioscience and 0 mentions for Applied Therapeutics. Yarrow Bioscience's average media sentiment score of 0.61 beat Applied Therapeutics' score of 0.00 indicating that Yarrow Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Applied Therapeutics	Neutral
Yarrow Bioscience	Positive

Yarrow Bioscience has lower revenue, but higher earnings than Applied Therapeutics. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
Yarrow Bioscience	$570K	92.33	-$26.48M	-$14.64	N/A

Applied Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, Yarrow Bioscience has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market.

Summary

Yarrow Bioscience beats Applied Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Applied Therapeutics compare to Xilio Therapeutics?

Applied Therapeutics (NASDAQ:APLT) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Applied Therapeutics currently has a consensus target price of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Applied Therapeutics is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Xilio Therapeutics had 3 more articles in the media than Applied Therapeutics. MarketBeat recorded 3 mentions for Xilio Therapeutics and 0 mentions for Applied Therapeutics. Xilio Therapeutics' average media sentiment score of 0.72 beat Applied Therapeutics' score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Applied Therapeutics	Neutral
Xilio Therapeutics	Positive

Applied Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -34.06%. Xilio Therapeutics' return on equity of -71.99% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Xilio Therapeutics	-34.06%	-71.99%	-20.43%

Applied Therapeutics has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.15, suggesting that its share price is 115% less volatile than the broader market.

Xilio Therapeutics has higher revenue and earnings than Applied Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
Xilio Therapeutics	$43.77M	1.36	-$35.04M	-$1.64	N/A

98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by company insiders. Comparatively, 7.5% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Applied Therapeutics beats Xilio Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Applied Therapeutics compare to Boundless Bio?

Applied Therapeutics (NASDAQ:APLT) and Boundless Bio (NASDAQ:BOLD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Applied Therapeutics currently has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Applied Therapeutics is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Applied Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, Boundless Bio has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market.

In the previous week, Boundless Bio had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for Boundless Bio and 0 mentions for Applied Therapeutics. Boundless Bio's average media sentiment score of 1.79 beat Applied Therapeutics' score of 0.00 indicating that Boundless Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Applied Therapeutics	Neutral
Boundless Bio	Very Positive

Boundless Bio has lower revenue, but higher earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A

Boundless Bio's return on equity of -70.89% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Boundless Bio	N/A	-70.89%	-47.37%

98.3% of Applied Therapeutics shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by company insiders. Comparatively, 23.1% of Boundless Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Boundless Bio beats Applied Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Applied Therapeutics compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and Applied Therapeutics (NASDAQ:APLT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

98.3% of Applied Therapeutics shares are held by institutional investors. 58.0% of eXoZymes shares are held by insiders. Comparatively, 1.6% of Applied Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, eXoZymes had 2 more articles in the media than Applied Therapeutics. MarketBeat recorded 2 mentions for eXoZymes and 0 mentions for Applied Therapeutics. eXoZymes' average media sentiment score of 1.18 beat Applied Therapeutics' score of 0.00 indicating that eXoZymes is being referred to more favorably in the media.

Company	Overall Sentiment
eXoZymes	Positive
Applied Therapeutics	Neutral

Applied Therapeutics has a consensus price target of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

eXoZymes' return on equity of -292.15% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-292.15%	-158.66%
Applied Therapeutics	N/A	-340.84%	-175.00%

eXoZymes has a beta of 3.19, meaning that its share price is 219% more volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market.

eXoZymes has higher earnings, but lower revenue than Applied Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	N/A	N/A	-$9.16M	-$1.19	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

Summary

eXoZymes beats Applied Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Applied Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APLT vs. The Competition

Export

Metric	Applied Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.86M	$3.92B	$7.24B	$13.22B
Dividend Yield	N/A	3.65%	2.53%	22.58%
P/E Ratio	-1.03	13.53	275.62	25.87
Price / Sales	15.86	1,176.76	580.40	79.65
Price / Cash	N/A	39.46	27.30	36.12
Price / Book	0.21	17.37	10.84	6.11
Net Income	-$105.62M	-$22.69M	$3.50B	$380.72M
7 Day Performance	N/A	-2.80%	-1.85%	-2.16%
1 Month Performance	N/A	-8.97%	-4.63%	-4.09%
1 Year Performance	-89.05%	13.21%	6.16%	0.67%

Applied Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APLT Applied Therapeutics	N/A	$0.10 flat	$1.00 +870.9%	N/A	$15.86M	$1M	N/A	30
KVAC Keen Vision Acquisition	N/A	$11.51 flat	N/A	N/A	$63.37M	N/A	N/A	N/A
YARW Yarrow Bioscience	2.1799 of 5 stars	$23.60 +4.8%	$58.00 +145.8%	N/A	$60.12M	$570K	N/A	30
XLO Xilio Therapeutics	0.1413 of 5 stars	$8.91 -1.5%	N/A	-18.6%	$59.55M	$43.77M	N/A	76
BOLD Boundless Bio	1.2956 of 5 stars	$2.59 +3.2%	N/A	+100.8%	$57.10M	N/A	N/A	28	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APLT) was last updated on 10/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Applied Therapeutics (APLT) Competitors

APLT vs. KVAC, YARW, XLO, BOLD, and EXOZ

How does Applied Therapeutics compare to Keen Vision Acquisition?

Summary

How does Applied Therapeutics compare to Yarrow Bioscience?

Summary

How does Applied Therapeutics compare to Xilio Therapeutics?

Summary

How does Applied Therapeutics compare to Boundless Bio?

Summary

How does Applied Therapeutics compare to eXoZymes?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLT vs. The Competition

Applied Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Applied Therapeutics (APLT) Competitors

APLT vs. KVAC, YARW, XLO, BOLD, and EXOZ

How does Applied Therapeutics compare to Keen Vision Acquisition?

Do analysts rate KVAC or APLT?

Which has preferable earnings & valuation, KVAC or APLT?

Which has more volatility & risk, KVAC or APLT?

Is KVAC or APLT more profitable?

Does the media favor KVAC or APLT?

Do insiders and institutionals believe in KVAC or APLT?

Summary

How does Applied Therapeutics compare to Yarrow Bioscience?

Do insiders and institutionals have more ownership in APLT or YARW?

Do analysts recommend APLT or YARW?

Is APLT or YARW more profitable?

Does the media refer more to APLT or YARW?

Which has higher valuation & earnings, APLT or YARW?

Which has more risk & volatility, APLT or YARW?

Summary

How does Applied Therapeutics compare to Xilio Therapeutics?

Do analysts rate APLT or XLO?

Does the media prefer APLT or XLO?

Is APLT or XLO more profitable?

Which has more volatility and risk, APLT or XLO?

Which has stronger earnings & valuation, APLT or XLO?

Do insiders & institutionals hold more shares of APLT or XLO?

Summary

How does Applied Therapeutics compare to Boundless Bio?

Do analysts rate APLT or BOLD?

Which has more volatility and risk, APLT or BOLD?

Does the media refer more to APLT or BOLD?

Which has better earnings & valuation, APLT or BOLD?

Is APLT or BOLD more profitable?

Do insiders & institutionals believe in APLT or BOLD?

Summary

How does Applied Therapeutics compare to eXoZymes?

Do institutionals & insiders have more ownership in EXOZ or APLT?

Does the media favor EXOZ or APLT?

Do analysts rate EXOZ or APLT?

Is EXOZ or APLT more profitable?

Which has more volatility & risk, EXOZ or APLT?

Which has better valuation and earnings, EXOZ or APLT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLT vs. The Competition

Applied Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools